Gong, C.; Liu, C.; Tao, Z.; Zhang, J.; Wang, L.; Cao, J.; Zhao, Y.; Xie, Y.; Hu, X.; Yang, Z.;
et al. Temporal Heterogeneity of HER2 Expression and Spatial Heterogeneity of 18F-FDG Uptake Predicts Treatment Outcome of Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer. Cancers 2022, 14, 3973.
https://doi.org/10.3390/cancers14163973
AMA Style
Gong C, Liu C, Tao Z, Zhang J, Wang L, Cao J, Zhao Y, Xie Y, Hu X, Yang Z,
et al. Temporal Heterogeneity of HER2 Expression and Spatial Heterogeneity of 18F-FDG Uptake Predicts Treatment Outcome of Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer. Cancers. 2022; 14(16):3973.
https://doi.org/10.3390/cancers14163973
Chicago/Turabian Style
Gong, Chengcheng, Cheng Liu, Zhonghua Tao, Jian Zhang, Leiping Wang, Jun Cao, Yannan Zhao, Yizhao Xie, Xichun Hu, Zhongyi Yang,
and et al. 2022. "Temporal Heterogeneity of HER2 Expression and Spatial Heterogeneity of 18F-FDG Uptake Predicts Treatment Outcome of Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer" Cancers 14, no. 16: 3973.
https://doi.org/10.3390/cancers14163973
APA Style
Gong, C., Liu, C., Tao, Z., Zhang, J., Wang, L., Cao, J., Zhao, Y., Xie, Y., Hu, X., Yang, Z., & Wang, B.
(2022). Temporal Heterogeneity of HER2 Expression and Spatial Heterogeneity of 18F-FDG Uptake Predicts Treatment Outcome of Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer. Cancers, 14(16), 3973.
https://doi.org/10.3390/cancers14163973